Rocket Pharmaceuticals Inc

NASDAQ:RCKT   4:00:00 PM EDT
19.88
+1.49 (+8.10%)
6:19:35 PM EDT: $20.45 +0.57 (+2.87%)
Products, Regulatory

Rocket Pharmaceuticals Announces Positive Updates From Phase 1 Clinical Trial

Published: 09/30/2022 11:36 GMT
Rocket Pharmaceuticals Inc (RCKT) - Rocket Pharmaceuticals Announces Positive Updates From Phase 1 Clinical Trial for Rp-a501 in Danon Disease at the Heart Failure Society of America (hfsa) Annual Scientific Meeting 2022.
Rocket Pharmaceuticals Inc - Rp-a501 Was Generally Well Tolerated With Manageable Safety Profile Across Pediatric and Adult Cohorts.
Rocket Pharmaceuticals Inc - FDA Feedback on Rp-a501 Pivotal Study Design and Endpoints Anticipated Later This Year.
Rocket Pharmaceuticals Inc - Strength of Clinical Data in Rp-a501 Presented to Date Expected to Support Phase 2 Pivotal Study.
Rocket Pharmaceuticals - Results of Rp-a501 Show Sustained Clinical Benefit Across All Parameters in Adult Patients With Up to 36 Months of Follow-up.